Manufacturer Patient Assistance Programs for Insulin and Blood Sugar Medications

What Manufacturer Patient Assistance Programs Actually Provide

Manufacturer patient assistance programs (PAPs) supply brand-name medications at no cost to patients who meet income and insurance criteria. For insulin specifically, these programs ship 90-day supplies directly to patients or to their prescriber's office, bypassing the pharmacy altogether.

The three companies that control over 90% of U.S. insulin sales each run distinct programs. Eli Lilly's Lilly Cares Foundation covers Humalog, Humulin, and Basaglar. Novo Nordisk's PAP covers NovoLog, Levemir, Tresiba, and Fiasp. Sanofi's Patient Connection covers Lantus, Toujeo, and Apidra [1]. Each program requires proof of U.S. residency, a valid prescription, and household income documentation. Patients enrolled in any government insurance (Medicare, Medicaid, VA, TRICARE) generally cannot access PAPs for drugs covered by their plan, though exceptions exist for those in the Medicare coverage gap.

A 2023 analysis in Diabetes Care found that only 2.1% of eligible patients actually enrolled in available PAPs, despite an estimated 1.3 million Americans rationing insulin due to cost [2]. The gap between eligibility and enrollment represents a failure of awareness, not availability.

The $35 Insulin Cap Under the Inflation Reduction Act

The Inflation Reduction Act (IRA), signed August 2022, capped Medicare Part D and Part B insulin copays at $35 per month per covered product starting January 1, 2023 [3]. This applies to all insulin formulations on a plan's formulary, with no deductible required.

For Medicare beneficiaries, this single provision reduced average annual insulin spending from $572 to approximately $420, according to CMS data from the first full year of implementation [4]. The cap does not apply to commercial insurance or the uninsured, which is precisely where manufacturer programs fill the gap. Lilly voluntarily extended its $35 cap to all commercial patients through the Insulin Value Program, and in March 2024 cut its list price for Humalog and Humulin by 70%, bringing the WAC (wholesale acquisition cost) to $66.40 per vial for Humalog [5].

The broader Part D redesign that took effect January 2025 capped total annual out-of-pocket spending at $2,000 across all Part D drugs. For patients on multiple insulins plus oral agents, this ceiling may bind before the per-product $35 cap becomes relevant.

Program-by-Program Breakdown: Eli Lilly

Lilly operates two distinct pathways. The Lilly Insulin Value Program is a savings card (not a PAP) that caps cost at $35/month for up to two insulin prescriptions, available to anyone with commercial insurance or no insurance. No income verification is required. Enrollment takes under five minutes online [5].

The Lilly Cares Foundation PAP is for patients without insurance and with household income at or below 400% FPL. Approved patients receive free insulin shipped to their provider every 90 days. The application requires a prescriber signature, proof of income (tax return or two pay stubs), and a statement confirming no prescription drug coverage. Processing takes 4-6 weeks from complete application to first shipment.

Lilly also sells authorized generic Insulin Lispro at a list price of $25 per vial and Insulin Lispro Protamine/Lispro (generic Humalog Mix) at similar pricing. These generics require no enrollment and are available at any pharmacy [6].

Program-by-Program Breakdown: Novo Nordisk

Novo Nordisk's patient assistance program covers NovoLog (insulin aspart), Levemir (insulin detemir), Tresiba (insulin degludec), and Fiasp (faster-acting insulin aspart). Eligibility requires U.S. residency, no prescription insurance, and adjusted gross income ≤400% FPL [7].

For commercially insured patients, Novo Nordisk offers the My$99Insulin program, which caps monthly costs at $99 for up to three vials or two packs of FlexPens. The NovoCare savings card can reduce copays to as low as $0 for patients whose insurance covers the product but assigns a high copay.

Novo Nordisk also manufactures Novolin R, Novolin N, and Novolin 70/30, which are sold over-the-counter at Walmart under the ReliOn brand for $72.88 per vial. These older human insulins require no prescription in most states, though they carry higher hypoglycemia risk compared to analog insulins [8]. The American Diabetes Association notes that while ReliOn insulin has saved lives, it should not be considered equivalent to modern rapid- and long-acting analogs for most treatment regimens [9].

Program-by-Program Breakdown: Sanofi

Sanofi's Insulins Valyou Savings Program provides Lantus (insulin glargine), Toujeo (concentrated glargine), and Apidra (insulin glulisine) at $35 per month for uninsured patients. Unlike full PAPs, Valyou works at the pharmacy counter with a savings card, so there is no shipment delay [10].

The Sanofi Patient Connection PAP covers patients with no insurance and income ≤400% FPL, supplying free medications for renewable 12-month periods. Sanofi also offers copay cards for commercially insured patients, reducing out-of-pocket costs by up to $100 per prescription fill.

Sanofi's biosimilar insulin glargine (Semglee, marketed with interchangeable designation) carries a list price approximately 65% lower than branded Lantus. The interchangeable designation means pharmacists can substitute Semglee for Lantus without prescriber authorization in most states [11].

CGM Costs and Manufacturer Assistance

Continuous glucose monitors (CGMs) represent a growing cost center for diabetes management. The Dexcom G7 carries a retail price of approximately $350-$400 per month (transmitter plus sensors). The Abbott FreeStyle Libre 3 runs approximately $150-$180 per month without insurance [12].

Dexcom offers a $0 copay program for commercially insured patients, covering up to $200 in copay costs per fill. Abbott's FreeStyle Libre savings card similarly reduces commercial copays to $0 for eligible patients. Neither program covers uninsured patients directly, though both manufacturers have PAPs for those with income below threshold.

Medicare Part B began covering CGMs as durable medical equipment in 2017 under the "therapeutic CGM" benefit, requiring a diagnosis of diabetes with insulin use and documentation of frequent glucose testing. The typical 20% Part B coinsurance on a CGM can reach $70-$80/month, which is where manufacturer copay cards cannot legally apply (due to the Anti-Kickback Statute prohibition on reducing cost-sharing for Medicare beneficiaries) [13].

A study published in Annals of Internal Medicine found that CGM use in type 2 diabetes patients on basal insulin reduced A1C by 0.4% over 8 months compared to fingerstick monitoring alone (MOBILE trial, N=175) [14]. This clinical benefit supports insurance coverage arguments but does not reduce out-of-pocket costs for patients fighting prior authorization denials.

GoodRx, Mark Cuban Cost Plus, and Generic Insulin Pricing

GoodRx coupons do not stack with manufacturer PAPs or insurance, but they offer an alternative pricing pathway at retail pharmacies. As of early 2026, GoodRx lists Insulin Lispro (generic Humalog) at $30-$55 per vial depending on pharmacy, Insulin Glargine (generic Lantus, Semglee) at $70-$120 per box of five pens, and Novolin R at $40-$60 per vial [15].

Mark Cuban Cost Plus Drugs (costplusdrugs.com) sells generic Insulin Glargine pens at $52.20 per five-pack (a 15% markup on manufacturer cost plus $5 pharmacy fee plus $5 shipping). This transparent pricing model bypasses PBM negotiations entirely.

The generic insulin market has expanded significantly since 2020. Civica Rx, the nonprofit generic manufacturer, announced insulin biosimilars at $30 per vial and $55 per five-pack of pens, though distribution remains limited to partner health systems and select pharmacy chains [16].

For patients choosing between these options, the decision matrix is straightforward:

• Medicare patients: the $35 cap applies automatically at any in-network pharmacy
• Commercially insured with high copay: manufacturer savings cards first, GoodRx second
• Uninsured with income <400% FPL: full PAP (free product)
• Uninsured with income >400% FPL: Lilly Value Program ($35/month), Sanofi Valyou ($35/month), or authorized generics at retail

How to Apply: Step-by-Step Process

Each manufacturer PAP follows a similar workflow. The patient or caregiver downloads the application from the manufacturer's website (LillyCares.com, NovoCare.com, SanofiPatientConnection.com). A prescriber must sign the application confirming the diagnosis, medication, and dose. Income documentation accompanies the form. Most programs accept electronic submission.

Processing timelines range from 2-8 weeks. Lilly Cares averages 4 weeks. Novo Nordisk's PAP averages 6 weeks. Sanofi Patient Connection averages 3-4 weeks. During this gap, patients can use savings cards or GoodRx to bridge supply [17].

Renewals are required annually. Most programs send reminder notices 30 days before expiration. Patients whose income changes mid-year (job loss, retirement) can submit a new application immediately without waiting for the renewal period.

A common failure point: applications rejected for incomplete prescriber information. The prescriber section requires NPI number, DEA number (for controlled substances, not insulin), office address, and a wet or electronic signature. Pre-filling this section before the clinic visit reduces rejection rates.

Oral Diabetes Medications and GLP-1 Receptor Agonists

PAPs extend beyond insulin. Metformin, the first-line oral agent for type 2 diabetes, costs $4-$10/month as a generic and rarely requires assistance. Branded SGLT2 inhibitors (Jardiance, Farxiga) and GLP-1 receptor agonists (Ozempic, Mounjaro, Trulicity) each run $800-$1,200/month at list price [18].

Boehringer Ingelheim's savings card for Jardiance (empagliflozin) reduces commercial copays to $10/month. AstraZeneca's Farxiga savings card offers $0 copays for eligible commercially insured patients. These cards have maximum annual benefit caps ($3,000-$5,000/year typically), which may not cover the full cost at all pharmacies.

For GLP-1 agonists used in diabetes (distinct from obesity-only indications), manufacturer savings programs differ from the weight-loss market. Novo Nordisk's savings card for Ozempic in type 2 diabetes covers up to $150 off each fill, while Lilly's card for Mounjaro offers $25 copays for commercially insured patients with a diabetes diagnosis on file [19].

The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide 0.5 mg and 1.0 mg reduced major adverse cardiovascular events by 26% (HR 0.74, 95% CI 0.58-0.95) in patients with type 2 diabetes and established cardiovascular disease [20]. This cardiovascular benefit, now reflected in FDA labeling, strengthens the prior authorization argument for insurers who initially deny coverage.

State-Level Programs and Safety-Net Options

Forty-three states plus Washington, D.C. have enacted insulin pricing protections of varying strength. Colorado was first in 2019, capping copays at $100/month. By 2026, at least 22 states cap copays at $25-$50 per 30-day supply for state-regulated commercial plans [21].

These state caps do not apply to self-insured employer plans (governed by ERISA), which cover approximately 65% of commercially insured Americans. For these patients, manufacturer programs remain the primary cost-reduction pathway.

Federally Qualified Health Centers (FQHCs) access the 340B Drug Pricing Program, purchasing insulin at 25-50% below wholesale cost. Patients seen at FQHCs may receive insulin at significantly reduced prices regardless of insurance status, though availability varies by site and formulary [22].

"The combination of the $35 Medicare cap, state-level copay ceilings, and manufacturer programs has created a patchwork system where the patient's insurance type determines which cost pathway applies," noted Dr. Jing Luo, an internal medicine physician and drug pricing researcher at the University of Pittsburgh, in a 2024 JAMA Internal Medicine commentary [23].

What the Data Shows About Insulin Affordability in 2026

The IQVIA Institute reported that net insulin prices (after rebates) fell 30% between 2019 and 2024, driven by biosimilar competition, the IRA cap, and voluntary manufacturer reductions [24]. The average patient out-of-pocket cost for a 30-day insulin supply dropped from $55 in 2020 to $28 in 2024 for Medicare beneficiaries and from $42 to $35 for commercially insured patients.

"The $35 cap has essentially become the ceiling for insured patients, with manufacturer programs serving as the floor for uninsured populations," stated the American Diabetes Association in its 2025 Standards of Care update [9].

Yet gaps remain. A CDC analysis using NHIS data found that 16.4% of insulin users reported cost-related medication non-adherence in 2023, down from 22.2% in 2021 but still representing approximately 1.1 million Americans skipping doses, rationing vials, or delaying refills [25].